Jaenisch, Muraru, and Pandey join PharmTech's Cole to discuss FDA's generative AI paper, ARPA-H's SURPASS trials, and AI accountability.
|Articles|May 15, 2020
- Pharmaceutical Technology-05-15-2020
- Volume 2020 eBook
- Issue 2
Considerations in Contamination Control
Author(s)Susan Haigney
A contamination control strategy can prevent contamination in sterile product manufacturing. The right system, equipment, and personnel training are also essential to mitigate risk.
Advertisement
Pharmaceutical Technology spoke with Richard Denk, senior consultant aseptic processing and containment, SKAN AG, about the risks of contamination in biopharmaceutical manufacturing and how this risk can be mitigated.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing, May 2020
May 2020
Pages: 38–42
Citation
When referring to this article, please cite it as S. Haigney, “Considerations in Contamination Control," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2020).
Articles in this issue
over 6 years ago
On Point: Biologics Drive Growth in Pre-Filled Syringesover 6 years ago
Instrumenting Single-Use Processesover 6 years ago
Best systems and equipment for contamination controlover 6 years ago
Building Data Quality In Generates Quality Data Outover 6 years ago
Detecting Contamination in Cell Therapiesover 6 years ago
Optimizing Viral Vector Manufacturing for Gene Therapyover 6 years ago
Minimizing Contamination During Biopharma R&Dover 6 years ago
Complications in Process Simulation ExecutionAdvertisement
Related to this article
Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Q&A: Patient-Centric Drug Development Should Start at Product Definition
2
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
3
PharmTech AI Pulse Check: AI Watermark Vulnerability
4
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
5